Custom service

Stable Cell Line Services

A production cell that holds its output across every batch.

Hosts: CHO-K1, CHO-S, HEK293; NS0 on requestSelection: GS/MSX, DHFR/MTX, puromycin, CRISPR knock-inTitre: 0.5–5 g/L for antibodies after amplification

Transient transfection answers the question 'does this protein express'. A stable cell line answers 'can this protein be supplied, repeatedly, for years, under a documented process'. The difference is three to four months of work and a cell bank, and it is worth paying for whenever the protein has a future beyond the first batch.

The line is built on a selection system chosen against the titre required. GS or DHFR systems allow gene amplification, pushing titres toward grams per litre; puromycin-only selection is faster but caps lower; CRISPR knock-in at a defined locus trades some titre for predictability, since a single documented integration site removes the position effects that make random integrants variable.

Cloning is the slow step and cannot be compressed safely. Single cells are deposited and expanded over four to six weeks, screened by specific productivity rather than by the titre of a crowded well, and the winners are passaged for sixty generations with productivity and growth measured throughout. A clone that decays before passage forty is discarded, because a production line that drifts is worse than no line at all.

Stable cell lines are built for proteins supplied repeatedly: reference standards, diagnostic reagents, in vivo study materials and anything approaching a regulated submission. They decouple supply from transfection lots and from the variability of transient expression.

They are unnecessary for a single research batch, where transient expression delivers protein in three weeks, and they are a poor investment for a protein still being optimised — build the line once the construct is final.

Each line is delivered with cloning records, growth and productivity curves, the sixty-passage stability dataset, sterility and mycoplasma results, and identity confirmation. Bank documentation includes passage number and viable cell count for every vial.

Service Highlights

  • Selection matched to titre. GS/MSX or DHFR/MTX for amplified expression; CRISPR knock-in where a defined locus matters more than maximum titre.
  • Productivity-first screening. Clones ranked by specific productivity per cell per day, which predicts bioreactor performance better than well titre.
  • Documented monoclonality. Limiting dilution with statistical support or single-cell deposition with imaging evidence.
  • Sixty-passage stability. Productivity and growth curves reported for the full study, not just the first and last points.
  • Serum-free suspension. Adapted before banking, so the line is ready for bioreactor production without further development.
  • Two-tier cell bank. Master and working banks with passage number, viability and productivity recorded per vial.

How the work runs

  1. Vector and host selection

    Promoter, selection marker and host cell chosen against the titre target and the regulatory context.

  2. Transfection and selection

    Electroporation or lipid transfection, followed by selection and, where used, gene amplification under MSX or MTX.

  3. Pool characterisation

    The surviving pool is expanded and its productivity measured in a fed-batch run before cloning is attempted.

  4. Clonal selection

    Single-cell deposition or limiting dilution, expansion over four to six weeks, and screening by specific productivity.

  5. Stability study

    Top clones passaged to sixty generations with titre and growth measured every ten passages.

  6. Banking

    Master and working banks frozen, tested for sterility and mycoplasma, with identity confirmed.

Specifications & timeline

Hosts
CHO-K1, CHO-S, HEK293; NS0 on request
Selection
GS/MSX, DHFR/MTX, puromycin, CRISPR knock-in
Titre
0.5–5 g/L for antibodies after amplification
Stability
≥60 passages documented
Timeline
10–16 weeks from vector to bank

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.